{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:09:35Z","timestamp":1792055375361,"version":"4.4.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignancy is a manifestation of acquired defects in regulatory circuits that direct normal cell proliferation and homeostasis. Most of these circuits operate through cell autonomous pathways, whereas others potentially involve the neighboring microenvironment. We report that the metalloprotease ADAM17 plays a pivotal role in several acquired tumor cell capabilities by mediating the availability of soluble transforming growth factor-\u03b1, an epidermal growth factor receptor (EGFR) ligand, and thus the establishment of a key autocrine signaling pathway. Silencing of ADAM17 in human renal carcinoma cell lines corrects critical features associated with cancer cells, including growth autonomy, tumor inflammation, and tissue invasion. Highly malignant renal carcinoma cancer cells fail to form in vivo tumors in the absence of ADAM17, confirming the essential function of this molecule in tumorigenesis. These data show that ligand shedding is a crucial step in endogenous EGFR activation and endorse prospective therapeutic strategies targeting ADAM17 in human cancer. (Cancer Res 2006; 66(16): 8083-90)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-1595","type":"journal-article","created":{"date-parts":[[2006,8,15]],"date-time":"2006-08-15T17:20:57Z","timestamp":1155662457000},"page":"8083-8090","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17"],"prefix":"10.1158","volume":"66","author":[{"given":"Aleksandra","family":"Franovic","sequence":"first","affiliation":[{"name":"1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Robert","sequence":"additional","affiliation":[{"name":"1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlene","family":"Smith","sequence":"additional","affiliation":[{"name":"1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Kurban","sequence":"additional","affiliation":[{"name":"2McGill Cancer Center and Department of Biochemistry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnim","family":"Pause","sequence":"additional","affiliation":[{"name":"2McGill Cancer Center and Department of Biochemistry, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshman","family":"Gunaratnam","sequence":"additional","affiliation":[{"name":"1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,8,15]]},"reference":[{"key":"2022061622130336900_B1","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000; 100: 57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061622130336900_B2","doi-asserted-by":"crossref","unstructured":"Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature\u20082002; 418: 823.","DOI":"10.1038\/418823a"},{"key":"2022061622130336900_B3","doi-asserted-by":"crossref","unstructured":"Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med\u20082004; 10: 789\u201399.","DOI":"10.1038\/nm1087"},{"key":"2022061622130336900_B4","doi-asserted-by":"crossref","unstructured":"Brattain MG, Howell G, Sun LZ, Willson JK. Growth factor balance and tumor progression. Curr Opin Oncol\u20081994; 6: 77\u201381.","DOI":"10.1097\/00001622-199401000-00011"},{"key":"2022061622130336900_B5","doi-asserted-by":"crossref","unstructured":"Pardee AB. G1 events and regulation of cell proliferation. Science\u20081989; 246: 603\u20138.","DOI":"10.1126\/science.2683075"},{"key":"2022061622130336900_B6","doi-asserted-by":"crossref","unstructured":"Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature\u20081985; 313: 745\u20137.","DOI":"10.1038\/313745a0"},{"key":"2022061622130336900_B7","unstructured":"Humes HD, Beals TF, Cieslinski DA, Sanchez IO, Page TP. Effects of transforming growth factor-\u03b2, transforming growth factor-\u03b1, and other growth factors on renal proximal tubule cells. Lab Invest\u20081991; 64: 538\u201345."},{"key":"2022061622130336900_B8","doi-asserted-by":"crossref","unstructured":"Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor \u03b1 in normal human adult kidney and enhanced expression of transforming growth factors \u03b1 and \u03b21 in renal cell carcinoma. Cancer Res\u20081989; 49: 6972\u20135.","DOI":"10.3727\/095535489820874904"},{"key":"2022061622130336900_B9","doi-asserted-by":"crossref","unstructured":"de Paulsen N, Brychzy A, Fournier MC, et al. Role of transforming growth factor-\u03b1 in von Hippel-Lindau (VHL)(\u2212\/\u2212) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A\u20082001; 98: 1387\u201392.","DOI":"10.1073\/pnas.031587498"},{"key":"2022061622130336900_B10","unstructured":"Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor \u03b1 is a target for the von Hippel-Lindau tumor suppressor. Cancer Res\u20081998; 58: 226\u201331."},{"key":"2022061622130336900_B11","unstructured":"Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor \u03b1. Cancer Res\u20081992; 52: 3335\u20139."},{"key":"2022061622130336900_B12","unstructured":"Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor \u03b1 and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res\u20081989; 49: 3407\u201311."},{"key":"2022061622130336900_B13","unstructured":"Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor \u03b1 and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res\u20081990; 50: 3934\u20139."},{"key":"2022061622130336900_B14","doi-asserted-by":"crossref","unstructured":"Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-{\u03b1}\/epidermal growth factor receptor growth stimulatory pathway in VHL\u2212\/\u2212 renal cell carcinoma cells. J Biol Chem\u20082003; 278: 44966\u201374.","DOI":"10.1074\/jbc.M305502200"},{"key":"2022061622130336900_B15","doi-asserted-by":"crossref","unstructured":"Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL\u2212\/\u2212 renal cancer. Cancer Res\u20082005; 65: 5221\u201330.","DOI":"10.1158\/0008-5472.CAN-05-0169"},{"key":"2022061622130336900_B16","doi-asserted-by":"crossref","unstructured":"Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science\u20081998; 282: 1281\u20134.","DOI":"10.1126\/science.282.5392.1281"},{"key":"2022061622130336900_B17","doi-asserted-by":"crossref","unstructured":"Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-\u03b1 converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem\u20082002; 277: 12838\u201345.","DOI":"10.1074\/jbc.M112050200"},{"key":"2022061622130336900_B18","doi-asserted-by":"crossref","unstructured":"Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-\u03b1 in tumors. EMBO J\u20082003; 22: 1114\u201324.","DOI":"10.1093\/emboj\/cdg111"},{"key":"2022061622130336900_B19","doi-asserted-by":"crossref","unstructured":"Yang H, Jiang D, Li W, Liang J, Gentry LE, Brattain MG. Defective cleavage of membrane bound TGF leads to enhanced activation of the EGF receptor in malignant cells. Oncogene\u20082000; 19: 1901\u201314.","DOI":"10.1038\/sj.onc.1203513"},{"key":"2022061622130336900_B20","doi-asserted-by":"crossref","unstructured":"Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev\u20082003; 17: 7\u201330.","DOI":"10.1101\/gad.1039703"},{"key":"2022061622130336900_B21","doi-asserted-by":"crossref","unstructured":"Lovering F, Zhang Y. Therapeutic potential of TACE inhibitors in stroke. Curr Drug Targets CNS Neurol Disord\u20082005; 4: 161\u20138.","DOI":"10.2174\/1568007053544147"},{"key":"2022061622130336900_B22","doi-asserted-by":"crossref","unstructured":"Doggrell SA. TACE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs\u20082002; 11: 1003\u20136.","DOI":"10.1517\/13543784.11.7.1003"},{"key":"2022061622130336900_B23","doi-asserted-by":"crossref","unstructured":"Shao MX, Ueki IF, Nadel JA. Tumor necrosis factor \u03b1-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A\u20082003; 100: 11618\u201323.","DOI":"10.1073\/pnas.1534804100"},{"key":"2022061622130336900_B24","doi-asserted-by":"crossref","unstructured":"Bonicalzi M-E, Groulx I, de Paulsen N, Lee S. Role of exon 2-encoded \u03b2-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem\u20082001; 276: 1407\u201316.","DOI":"10.1074\/jbc.M008295200"},{"key":"2022061622130336900_B25","unstructured":"Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res\u20081998; 58: 4957\u201362."},{"key":"2022061622130336900_B26","doi-asserted-by":"crossref","unstructured":"Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med\u20081995; 1: 822\u20136.","DOI":"10.1038\/nm0895-822"},{"key":"2022061622130336900_B27","doi-asserted-by":"crossref","unstructured":"Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA\u20081995; 273: 564\u201370.","DOI":"10.1001\/jama.273.7.564"},{"key":"2022061622130336900_B28","doi-asserted-by":"crossref","unstructured":"Kaelin WG, Jr., Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med\u20081998; 243: 535\u20139.","DOI":"10.1046\/j.1365-2796.1998.00335.x"},{"key":"2022061622130336900_B29","doi-asserted-by":"crossref","unstructured":"Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A\u20081998; 95: 993\u20138.","DOI":"10.1073\/pnas.95.3.993"},{"key":"2022061622130336900_B30","doi-asserted-by":"crossref","unstructured":"Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res\u20082006; 66: 1313\u20139.","DOI":"10.1158\/0008-5472.CAN-05-2560"},{"key":"2022061622130336900_B31","doi-asserted-by":"crossref","unstructured":"Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell\u20081998; 1: 959\u201368.","DOI":"10.1016\/S1097-2765(00)80096-9"},{"key":"2022061622130336900_B32","doi-asserted-by":"crossref","unstructured":"Black RA. Tumor necrosis factor-[\u03b1] converting enzyme. Int J Biochem Cell Biol\u20082002; 34: 1\u20135.","DOI":"10.1016\/S1357-2725(01)00097-8"},{"key":"2022061622130336900_B33","doi-asserted-by":"crossref","unstructured":"Ikemoto S, Yoshida N, Narita K, et al. Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep\u20082003; 10: 1843\u20139.","DOI":"10.3892\/or.10.6.1843"},{"key":"2022061622130336900_B34","doi-asserted-by":"crossref","unstructured":"Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell\u20081996; 86: 353\u201364.","DOI":"10.1016\/S0092-8674(00)80108-7"},{"key":"2022061622130336900_B35","doi-asserted-by":"crossref","unstructured":"Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer\u20082002; 2: 563\u201372.","DOI":"10.1038\/nrc865"},{"key":"2022061622130336900_B36","doi-asserted-by":"crossref","unstructured":"Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-[\u03b1] and epidermal growth factor. Cell\u20081987; 50: 1131\u20137.","DOI":"10.1016\/0092-8674(87)90179-6"},{"key":"2022061622130336900_B37","doi-asserted-by":"crossref","unstructured":"Maheshwari G, Wiley HS, Lauffenburger DA. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J Cell Biol\u20082001; 155: 1123\u20138.","DOI":"10.1083\/jcb.200109060"},{"key":"2022061622130336900_B38","doi-asserted-by":"crossref","unstructured":"Sewell JM, Smyth JF, Langdon SP. Role of TGF[\u03b1] stimulation of the ERK, PI3 kinase and PLC[\u03b3] pathways in ovarian cancer growth and migration. Exp Cell Res\u20082005; 304: 305\u201316.","DOI":"10.1016\/j.yexcr.2004.11.007"},{"key":"2022061622130336900_B39","doi-asserted-by":"crossref","unstructured":"Lamszus K, Brockmann MA, Eckerich C, et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res\u20082005; 11: 4934\u201340.","DOI":"10.1158\/1078-0432.CCR-04-2270"},{"key":"2022061622130336900_B40","doi-asserted-by":"crossref","unstructured":"Nagano O, Murakami D, Hartmann D, et al. Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca2+ influx and PKC activation. J Cell Biol\u20082004; 165: 893\u2013902.","DOI":"10.1083\/jcb.200310024"},{"key":"2022061622130336900_B41","doi-asserted-by":"crossref","unstructured":"Beer S, Oleszewski M, Gutwein P, Geiger C, Altevogt P. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci\u20081999; 112: 2667\u201375.","DOI":"10.1242\/jcs.112.16.2667"},{"key":"2022061622130336900_B42","doi-asserted-by":"crossref","unstructured":"Huang J, Bridges LC, White JM. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell\u20082005; 16: 4982\u201391.","DOI":"10.1091\/mbc.e05-03-0258"},{"key":"2022061622130336900_B43","doi-asserted-by":"crossref","unstructured":"Bax DV, Messent AJ, Tart J, et al. Integrin {\u03b1}5{\u03b2}1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cells. J Biol Chem\u20082004; 279: 22377\u201386.","DOI":"10.1074\/jbc.M400180200"},{"key":"2022061622130336900_B44","doi-asserted-by":"crossref","unstructured":"Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol\u20082000; 2: 249\u201356.","DOI":"10.1038\/35010517"},{"key":"2022061622130336900_B45","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs\u20082003; 21: 99\u2013101.","DOI":"10.1023\/A:1022928612511"},{"key":"2022061622130336900_B46","doi-asserted-by":"crossref","unstructured":"Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs\u20082003; 21: 341\u201350.","DOI":"10.1023\/A:1025472712456"},{"key":"2022061622130336900_B47","unstructured":"Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res\u20082000; 6: 1518\u201323."},{"key":"2022061622130336900_B48","doi-asserted-by":"crossref","unstructured":"Dancey JE. Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol\u20082004; 22: 2975\u20137.","DOI":"10.1200\/JCO.2004.04.934"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/8083\/2552831\/8083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/8083\/2552831\/8083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T14:43:33Z","timestamp":1683557013000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/16\/8083\/526063\/Multiple-Acquired-Renal-Carcinoma-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,15]]},"references-count":48,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2006,8,15]]},"published-print":{"date-parts":[[2006,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-1595","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,15]]}}}